Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

@article{Ferm2006LongtermRA,
  title={Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).},
  author={Christophe Ferm{\'e} and Nicolas Mounier and Olivier Casasnovas and Pauline Brice and Marine Divin{\'e} and Anne Sonet and Fahdela Bouafia and Aspasia Bastard-Stamatoullas and Dominique Bordessoule and Laurent Voillat and Oum{\'e}daly Reman and Michel Blanc and Christian Gisselbrecht},
  journal={Blood},
  year={2006},
  volume={107 12},
  pages={
          4636-42
        }
}
From 1989 to 1996, 533 eligible patients with stage IIIB/IV Hodgkin lymphoma (HL) were randomly assigned to receive 6 cycles of hybrid MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/Adriamycin [doxorubicin], bleomycin, vinblastine; n = 266) or ABVPP (doxorubicin, bleomycin, vinblastine, procarbazine, prednisone; n = 267). Patients in complete remission (CR) or partial response of at least 75% after 6 cycles received 2 cycles of consolidation chemotherapy (CT) (n = 208) or… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

The past: what we have learned in the last decade.

  • Hematology. American Society of Hematology. Education Program
  • 2010

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

Long-term cause-specific mortality of patients treated for Hodgkin's disease.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
VIEW 1 EXCERPT

Similar Papers